指南与共识肝病

依据慢性肾脏病指南评估富马酸替诺福韦二吡呋酯在乙型肝炎患者中的肾脏安全性

Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
指南 / 共识 · Aliment Pharmacol Ther · 2018-04-25

该回顾性研究将253例接受富马酸替诺福韦二吡呋酯(TDF)的慢性乙型肝炎患者与506例接受恩替卡韦(ETV)者按倾向评分1:2匹配,依据KDIGO指南评估肾功能恶化。48个月内TDF组eGFR下降15.73 mL/min/1.73 m2,ETV组下降5.96 mL/min/1.73 m2(P<0.001);肾功能恶化累积发生率TDF组11.1% vs ETV组1.7%(P<0.001),TDF与肾功能恶化风险升高独立相关(HR 5.36)。

要点

  • 48个月内TDF组eGFR下降15.73 mL/min/1.73 m2,ETV组下降5.96 mL/min/1.73 m2(P<0.001)。
  • 肾功能恶化累积发生率TDF组11.1% vs ETV组1.7%(P<0.001)。
  • 调整后TDF与肾功能恶化风险升高独立相关(HR 5.36,95%CI 2.16-13.35)。

核心结论

  • 依据KDIGO指南,TDF与ETV相比与肾功能恶化风险升高相关。

研究设计与样本

  • 回顾性纳入2008年1月至2015年8月接受TDF或ETV单药治疗的慢性乙型肝炎患者。
  • 排除混杂情况后,253例TDF患者经倾向评分按1:2随机匹配506例ETV患者,匹配因素包括年龄、性别、肝硬化、慢性肾脏病(CKD)和估算肾小球滤过率(eGFR)。
  • 肾功能恶化定义为GFR分期下降并伴eGFR下降≥25%。

主要发现

  • 48个月内平均eGFR下降TDF组15.73 mL/min/1.73 m2(95%CI 13.76-17.70)vs ETV组5.96 mL/min/1.73 m2(95%CI 4.72-7.19),P<0.001。
  • 肾功能恶化累积发生率TDF组11.1%(95%CI 7.4-14.8)vs ETV组1.7%(95%CI 1.0-2.4),P<0.001。
  • 调整年龄、既存CKD和糖尿病后,TDF与肾功能恶化风险升高独立相关(HR 5.36,95%CI 2.16-13.35;P<0.001)。
  • 既存CKD(HR 6.71,95%CI 2.25-17.65)、蛋白尿(HR 3.39,95%CI 1.23-9.39)和血尿(HR 4.25,95%CI 1.32-13.68)也是肾功能不全的独立因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal dysfunction remains an issue in tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) patients. AIM: To evaluate renal safety of TDF according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. METHODS: We retrospectively recruited CHB patients who received either TDF or entecavir (ETV) monotherapy from January 2008 to August 2015. After excluding confounding conditions, 253 patients who received TDF were randomly matched 1:2 with 506 patients who received ETV through the propensity scores, which consisted of age, gender, cirrhosis, chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR). Renal function deterioration was defined as a drop in GFR category accompanied with a ≥25% eGFR decline. Cumulative incidences of and hazard ratios (HRs) for renal dysfunction were analysed. RESULTS: The mean eGFR decline was significantly greater in the TDF group over 48 months (TDF vs ETV: 15.73 mL/min/1.73 m2 , 95% confidence interval [CI]: 13.76-17.70 vs 5.96 mL/min/1.73 m2 , 95% CI: 4.72-7.19; P < 0.001). The cumulative incidence of renal function deterioration was significantly higher in the TDF group (TDF vs ETV: 11.1%, 95% CI: 7.4-14.8 vs 1.7%, 95% CI: 1.0-2.4; P < 0.001). After adjusting for age, pre-existing CKD and diabetes, TDF was independently associated with an increased risk of renal function deterioration (HR 5.36, 95% CI: 2.16-13.35; P < 0.001). Pre-existing CKD (HR 6.71, 95% CI: 2.25-17.65), proteinuria (HR 3.39, 95% CI: 1.23-9.39), and haematuria (HR 4.25, 95% CI: 1.32-13.68) were also independent factors of renal dysfunction. CONCLUSION: By following the KDIGO guidelines, we confirmed that TDF was associated with a higher risk of renal dysfunction as compared to ETV.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tsai HJ, Chuang YW, Lee SW, et al. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther. 2018. PMID: 29696665. doi:10.1111/apt.14682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。